Association of supratotal resection with progression-free survival, malignant transformation, and overall survival in lower-grade gliomas

被引:84
|
作者
Rossi, Marco [1 ,2 ]
Gay, Lorenzo [1 ,2 ]
Ambrogi, Federico [3 ]
Nibali, Marco Conti [1 ,2 ]
Sciortino, Tommaso [1 ,2 ]
Puglisi, Guglielmo [1 ,2 ]
Leonetti, Antonella [1 ,2 ]
Mocellini, Cristina [4 ]
Caroli, Manuela [5 ]
Cordera, Susanna [6 ]
Simonelli, Matteo [7 ]
Pessina, Federico [7 ]
Navarria, Piera [7 ]
Pace, Andrea [8 ]
Soffietti, Riccardo [9 ]
Ruda, Roberta [9 ]
Riva, Marco [1 ,2 ]
Bello, Lorenzo [1 ,2 ]
机构
[1] Univ Milan, Dept Oncol & Hematooncol, Neurosurg Oncol Unit, Milan, Italy
[2] IRCCS Ist Ortoped Galeazzi, Neurosurg Oncol Unit, Milan, Italy
[3] Univ Milan, Dept Clin Sci & Community Hlth, Lab Med Stat Biometry & Epidemiol GA Maccararo, Milan, Italy
[4] Osped Santa Croce & Carle, Neurooncol, Div Neurol, Cuneo, Italy
[5] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Neurochirurg, Milan, Italy
[6] Osped Reg Parini, Div Neurol, Neurooncol, Aosta, Italy
[7] IRCCS, Humanitas Canc Ctr, Humanitas Res Hosp, Rozzano, Italy
[8] Ist Nazl Tumori Regina Elena, Neurooncol, Rome, Italy
[9] Univ Torino, Citta Salute & Sci, Neurooncol, Turin, Italy
关键词
lower-grade gliomas; malignant progression-free survival; overall survival; progression-free survival; supratotal resection; RESPONSE ASSESSMENT; SURGICAL RESECTION; II GLIOMAS; DIFFUSE; SURGERY; NEUROONCOLOGY; MANAGEMENT; SAFETY;
D O I
10.1093/neuonc/noaa225
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Supratotal resection is advocated in lower-grade gliomas (LGGs) based on theoretical advantages but with limited verification of functional risk and data on oncological outcomes. We assessed the association of supratotal resection in molecularly defined LGGs with oncological outcomes. Methods. Included were 460 presumptive LGGs; 404 resected; 347 were LGGs, 319 isocitrate dehydrogenase (IDH)-mutated, 28 wildtype. All patients had clinical, imaging, and molecular data. Resection aimed at supratotal resection without any patient or tumor a priori selection. The association of extent of resection (EOR), categorized on volumetric fluid attenuated inversion recovery images as residual tumor volume, along with postsurgical management with progression-free survival (PFS), malignant (M)PFS, and overall survival (OS) assessed by univariate, multivariate, and propensity score analysis. The study mainly focused on IDH-mutated LGGs, the "typical LGGs." Results. Median follow-up was 6.8 years (interquartile range, 5-8). Out of 319 IDH-mutated LGGs, 190 (59.6%) progressed, median PFS: 4.7 years (95% CI: 4-5.3). Total and supratotal resection obtained in 39% and 35% of patients with IDH1-mutated tumors. In IDH-mutated tumors, most patients in the partial/subtotal group progressed, 82.4% in total, only 6 (5.4%) in supratotal. Median PFS was 29 months (95% CI: 25-36) in subtotal, 46 months (95% CI: 38-48) in total, while at 92 months, PFS in supratotal was 94.0%. There was no association with molecular subtypes and grade. At random forest analysis, PFS strongly associated with EOR, radiotherapy, and previous treatment. In the propensity score analysis, EOR associated with PFS (hazard ratio, 0.03; 95% CI: 0.01-0.13). MPFS occurred in 32.1% of subtotal total groups; 1 event in supratotal. EOR, grade III, previous treatment correlated to MPFS. At random forest analysis, OS associated with EOR as well. Conclusions. Supratotal resection strongly associated with PFS, MPFS, and OS in LGGs, regardless of molecular subtypes and grade, right from the beginning of clinical presentation.
引用
收藏
页码:812 / 826
页数:15
相关论文
共 50 条
  • [21] Gross Total Resection of Glioblastoma Improves Overall Survival and Progression-Free Survival Compared to Subtotal Resection or Biopsy Alone
    Khan, Muhammad B.
    Chakraborty, Shamik
    Boockvar, John A.
    NEUROSURGERY, 2016, 79 (06) : N12 - N13
  • [22] Modelling of overall survival by an association between progression-free and post-progression survival using a conditional distribution
    Belkacemi, Mohamed C.
    Castelli, Christel
    Remita, Mohamed R.
    Fournel, Pierre
    Daures, Jean P.
    STATISTICAL MODELLING, 2014, 14 (01) : 77 - 98
  • [23] Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the Progression-free Survival Endpoint
    Rosenberg, Aaron S.
    Facon, Thierry
    Parikh, Kejal
    Chung, Weiyuan
    Srinivasan, Shankar
    Kotey, Stanley
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (05): : 345 - +
  • [24] Progression-free survival as a surrogate for overall survival in advanced cancer.
    Gillies, Eric
    Holdai, Veera
    Cowall, David Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] OVERALL SURVIVAL VERSUS PROGRESSION-FREE SURVIVAL IN ONCOLOGY CLINICAL TRIALS
    Aissaoui, A.
    Bin Sawad, A.
    Turkistani, F.
    Aissaoui, N.
    VALUE IN HEALTH, 2016, 19 (07) : A717 - A717
  • [26] Progression-Free Survival as a Surrogate Marker of Overall Survival Is It the Good Question?
    Escudier, Bernard
    CANCER, 2011, 117 (12) : 2586 - 2587
  • [27] A statistical model for the dependence between progression-free survival and overall survival
    Fleischer, Frank
    Gaschler-Markefski, Birgit
    Bluhmki, Erich
    STATISTICS IN MEDICINE, 2009, 28 (21) : 2669 - 2686
  • [28] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M. E.
    Yelle, L.
    Lachaine, J.
    VALUE IN HEALTH, 2012, 15 (07) : A414 - A414
  • [29] PROGRESSION-FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER
    Beauchemin, C.
    Cooper, D.
    Lapierre, M.
    Yelle, L.
    Lachaine, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 119 - 120
  • [30] Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
    Broglio, Kristine R.
    Berry, Donald A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (23): : 1642 - 1649